Impact of the trade agreement between Europe and Canada on the costs of patented drugs
This study finds that the Comprehensive and Economic Trade Agreement (CETA) between the European Union and Canada will further tilt the balance towards the protection of brand-name drug manufacturers and their profits and away from Canadian consumers—resulting in significantly higher drug costs for Canadians. The study also examines the latest revelations about the tentative trade agreement, and asserts that the CETA will seriously impact the ability of Canadians to afford quality health care.
About the authors
Joel Lexchin
Joel Lexchin has been researching an writting about a wide range of pharmaceutical policy issues both in Canada and internationally for over 40 years. He taught health policy at York University from 2001 to 2016 and worked as a doctor in the emergency department at the University Health Network in Toronto. He is a member of the board of the Canadian Health Coalition and formerly the board of Canadian Doctors for Medicare.